|
Roche reports a strong start in 2019 and raises the outlook for the full-year
|
18 April 2019 |
|
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
|
20 March 2019 |
|
Roche enters into definitive merger agreement to acquire Spark Therapeutics
|
26 February 2019 |
|
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
|
21 January 2019 |
|
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
|
06 December 2018 |
|
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
|
25 October 2018 |
|
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
|
22 August 2018 |
|
Roche reports very strong performance in the first half of 2018
|
26 July 2018 |
|
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
|
19 July 2018 |
|
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
|
02 July 2018 |
|
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
|
25 June 2018 |
|
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
|
15 June 2018 |
|
FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
|
07 June 2018 |
|
FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
|
08 May 2018 |
|
Roche reports a strong start in 2018
|
30 April 2018 |
|
New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
|
24 April 2018 |
|
FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
|
17 April 2018 |
|
Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
|
21 February 2018 |
|
Roche purchases shares in tender offer for Ignyta, Inc.
|
08 February 2018 |
|
Roche reports good results in 2017
|
01 February 2018 |